StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Travere Therapeutics's total debt was $22.60M at Sep 30, 2018.

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2019Sep 30, 2018$22.60M–

More Travere Therapeutics figures

See a number that looks wrong?